Role of mitogen-activated protein (MAP) kinases in cardiovascular diseases

Cardiovascular Drug Reviews

Volumn 23, Issue 3, 2005, Pages 247-254

  Pandya, Nilesh ^a   Santani, Dev ^b   Jain, Sunita ^b  

^a C U SHAH UNIVERSITY   (India)

^b L M COLLEGE OF PHARMACY   (India)

Author keywords

Atherosclerosis; Cardiomyopathy; MAP kinase; Myocardial contractility

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA INTERFERON; BETA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NEW DRUG; STRESS ACTIVATED PROTEIN KINASE;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; DRUG DESIGN; ENZYME ACTIVITY; GENE CONTROL; HEART CONTRACTION; HEMATOPOIESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 27644472420     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2005.tb00169.x     Document Type: Review

References (37)

1. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
2. Boulton TG, Nye SH, Robbins DJ. ERKs: A family of protein-serine/ threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663-675.
3. Boulton TG, Cobb NH. Identification of multiple extracellular signal-regulated kinases (ERKs) with anti-peptide antibodies. Cell Regul 1991;2:357-371.
4. Cobb MH, Boulton TG, Robbins DJ. Extracellular signal-regulated kinases: ERKs in progress. Cell Regul 1991;2:965-978.
5. Todd JL, Tanner KG, Denu JM. Extracellular regulated kinases (ERK) 1 & ERK2 are authentic substrates for the dual specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J Biol Chem 1999;274:13271-13280.
6. Yang DD, Conze D, Whitmarsh AJ et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998;9:575-585.
7. Ono K, Han J. The P38 signal transduction pathway: Activation and function. Cell Signal 2000;12:1-13.
8. Foltz IN, Lee JC, Young PR. Hemopoietic growth factors with the exception of interleukin-4 activate the p38 mitogen-activated protein kinase pathway. J Biol Chem 1997;272:3296-3301.
9. Nagata Y, Moriguchi T, Nishida E, Tokodoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood 1997;90:929-934.
10. Verma A, Deb DK, Sassano A, et al. Activation of the p38 MAP kinase pathway mediates the suppressive effects of Type I interferons and transforming growth factor beta on normal hematopoiesis. J Biol Chem 2002;277:7726-7735.
11. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38 in erythropoietin expression: A role for stress kinases in erythropoiesis. Cell 2000;102:221-231.
12. Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 1999;31:1429-1434.
13. Cain BS, Meldrum DR, Meng X, et al. p38-MAPK inhibition decreases TNF production and enhances post-ischemic human myocardial function. J Surg Res 1999;83:7-12.
14. β (in adult mouse cardiomyocytes. J Biol Chem 2000;275:40635-40640.
15. Liao P, Wang SQ, Wang S, Zheng M, et al. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 2002;90:190-196.
16. Grossman W. Cardiac hypertrophy: Useful adaptation or pathologic process? Am J Med 1980;69:576-83.
17. Chien KR, Zhu H, Knowlton KU, et al. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993;55:77-95.
18. Chien KR, Grace AA. in: Braunwald E, Ed., Heart disease: A textbook of cardiovascular medicine. 5th Ed., Philadelphia: W. B. Saunders Co., 1996;1626-1649.
19. Yibin W, Shuang H, Valerie PS, Joan HB, Jiahuai H, Kenneth RC. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998;273:2161-2168.
20. Post GR, Goldstein D, Thuerauf D, Glembotski CC, Brown JH. Dissociation of p44 and p42 mitogen activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 1996;271:8452-8457.
21. Ramirez MT, Sah VP, Zhao XL, Hunter JJ, Chien KR, Brown JH. The MEKK-JNK pathway is stimulated by α-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem 1997;272:14057-14061.
22. Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med 1998;8:59-64.
23. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
24. Yoshizumi M, Tsuchiya K, Tamaki T. Signal transduction of reactive oxygen species and mitogen-activated protein kinases in cardiovascular disease. J Med Invest 2001;48:11-24.
25. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000;20:2175-83.
26. Patterson C, Ruef J, Madamanchi NR, et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that P47 (Phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999;274:19814-19822.
27. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. P22 phox is a critical component of the superoxide generating NADH/NADPH oxidase system and regulates angiotensin II induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317-23321.
28. Fei J, Veidt C, Soto U, Elsing C, Jahn L, Kreuzer J. Endothelin-1 and smooth muscle cells: Induction of jun amino terminal kinase through an oxygen radical-sensitive mechanism. Arterioscler Thromb Vasc Biol 2000;20:1244-1249.
29. Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC. Src and Cas mediate JNK activation but not ERK1/2 and P38 kinases by reactive oxygen species. J Biol Chem 2000;275:11706-11712.
30. Ishida M, Ishida T, Thomas SM, Berk BC. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res 1998;82:7-12.
31. Yoshizumi M, Kim S, Kagami S, Hamaguchi A. Effect of endothelin-1 on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 1998;125:1019-27.
32. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Tamaki T. Antioxidants inhibit JNK and P38 MAPK activation but not ERK1/2 activation by angiotensin II in rat aortic smooth muscle cells. Hypertens Res 2001;24:251-261.
33. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Suzaki Y, Abe S. Antioxidants inhibit endothelin-I induced proliferation of vascular smooth muscle cells via the inhibition of mitogen-activated protein (MAP) kinase and activator protein-1 (AP-1). Biochem Pharmacol 2002;64:1521-1531.
34. Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D. Role of caspases in ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004;94:370-376.
35. Bors W, Heller W, Michael C, Saran M. Flavonoids as antioxidants: Determination of radical-scavenging efficiencies. Methods Enzymol 1990;186:343-355.
36. Yoshizumi M, Tsuchiya K, Kirima K, Kyaw M, Suzaki Y, Tamaki T. Quercetin inhibits Shc- and phosphatidylinositol 3-kinase-mediated c-jun-N-terminal kinase activation by angiotensin II in cultured rat aortic smooth muscle cells. Mol Pharmacol 2001;60:656-65.
37. Moon SK, Cho GO, Jung SJ, Gal SW, Kwon TK, Lee YC. Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: Role of ERK1/2, cell cycle regulation, and matrix metalloproteinase-9. Biochem Biophys Res Commun 2003;301:1069-1078.